within Pharmacolibrary.Drugs.ATC.N;

model N05AF05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.44,
    Cl             = 0.23 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,
    adminCount     = 1,
    Vd             = 0.014199999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 9.96
  );

  annotation(Documentation(
    info ="<html><body><p>Zuclopenthixol is a typical antipsychotic drug of the thioxanthene class, primarily used for the treatment of schizophrenia and other psychotic disorders. It is available in several formulations, including oral and long-acting intramuscular preparations. The drug remains in clinical use for managing agitation, aggression, and psychosis, especially where adherence is a concern.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult psychiatric patients after oral administration.</p><h4>References</h4><ol><li><p>Correll, CU, et al., &amp; Saklad, SR (2021). Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. <i>CNS drugs</i> 35(1) 39–59. DOI:<a href=&quot;https://doi.org/10.1007/s40263-020-00779-5&quot;>10.1007/s40263-020-00779-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33507525/&quot;>https://pubmed.ncbi.nlm.nih.gov/33507525</a></p></li><li><p>Spanarello, S, &amp; La Ferla, T (2014). The pharmacokinetics of long-acting antipsychotic medications. <i>Current clinical pharmacology</i> 9(3) 310–317. DOI:<a href=&quot;https://doi.org/10.2174/15748847113089990051&quot;>10.2174/15748847113089990051</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23343447/&quot;>https://pubmed.ncbi.nlm.nih.gov/23343447</a></p></li><li><p>Tveito, M, et al., &amp; Høiseth, G (2021). Impact of age and CYP2D6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulation-an observational study including 2044 patients. <i>European journal of clinical pharmacology</i> 77(2) 215–221. DOI:<a href=&quot;https://doi.org/10.1007/s00228-020-03002-y&quot;>10.1007/s00228-020-03002-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33000414/&quot;>https://pubmed.ncbi.nlm.nih.gov/33000414</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05AF05;
